212 related articles for article (PubMed ID: 22973229)
1. The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
Luraghi P; Schelter F; Krüger A; Boccaccio C
Front Pharmacol; 2012; 3():164. PubMed ID: 22973229
[TBL] [Abstract][Full Text] [Related]
2. MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk.
Modica C; Tortarolo D; Comoglio PM; Basilico C; Vigna E
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544501
[TBL] [Abstract][Full Text] [Related]
3. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
5. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
7. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
Basilico C; Modica C; Maione F; Vigna E; Comoglio PM
Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242
[TBL] [Abstract][Full Text] [Related]
8. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.
Lee BS; Kang S; Kim KA; Song YJ; Cheong KH; Cha HY; Kim CH
Cell Death Dis; 2014 Apr; 5(4):e1159. PubMed ID: 24722284
[TBL] [Abstract][Full Text] [Related]
9. c-Met expression in renal cell carcinoma with bone metastases.
Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
[TBL] [Abstract][Full Text] [Related]
10. TNF-α promotes invasive growth through the MET signaling pathway.
Bigatto V; De Bacco F; Casanova E; Reato G; Lanzetti L; Isella C; Sarotto I; Comoglio PM; Boccaccio C
Mol Oncol; 2015 Feb; 9(2):377-88. PubMed ID: 25306394
[TBL] [Abstract][Full Text] [Related]
11. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing.
Xu KP; Yu FS
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2242-8. PubMed ID: 17460286
[TBL] [Abstract][Full Text] [Related]
12. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.
van der Horst EH; Chinn L; Wang M; Velilla T; Tran H; Madrona Y; Lam A; Ji M; Hoey TC; Sato AK
Neoplasia; 2009 Apr; 11(4):355-64. PubMed ID: 19308290
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
14. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
[TBL] [Abstract][Full Text] [Related]
15. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
Dai Y; Siemann DW
BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins.
Weimar IS; de Jong D; Muller EJ; Nakamura T; van Gorp JM; de Gast GC; Gerritsen WR
Blood; 1997 Feb; 89(3):990-1000. PubMed ID: 9028331
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.
Hara T; Kimura A; Miyazaki T; Tanaka H; Morimoto M; Nakai K; Soeda J
Biochem Biophys Rep; 2020 Mar; 21():100726. PubMed ID: 32055714
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]